Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.16Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 0.00%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a transformative period for FibroGen, with the sale of FibroGen China to AstraZeneca bringing in higher than expected proceeds and extending their financial runway significantly. There is notable progress in their clinical pipeline, particularly in the development of FG-3246 and FG-3180, with promising results from clinical trials. However, the company faced a significant decline in revenue and continued to operate at a net loss. While the highlights indicate strategic advancements and positive financial prospects, the revenue decline and continued net loss are concerning.Company Guidance
During the FibroGen First Quarter 2025 Earnings Conference Call, the company provided key financial and strategic guidance. The sale of FibroGen China to AstraZeneca is expected to close in Q3 2025, with total consideration now approximately $185 million, a $25 million increase from initial estimates. This transaction extends FibroGen's cash runway into the second half of 2027. The company remains focused on advancing its U.S. pipeline, particularly FG-3246 and FG-3180 for metastatic castration-resistant prostate cancer (mCRPC). FG-3246 demonstrated a median radiographic progression-free survival (rPFS) of 8.7 months in Phase 1, and FG-3180 received FDA clearance for its IND. FibroGen anticipates important FDA feedback on Roxadustat in anemia associated with lower-risk myelodysplastic syndromes by Q3. Full-year 2025 total revenue is projected between $4 million and $8 million, with operating expenses ranging from $70 million to $80 million, marking a 58% reduction from 2024.Increased Sale Proceeds from FibroGen China
The sale of FibroGen China to AstraZeneca now expected to bring approximately $185 million, a $25 million increase from initial guidance due to greater than expected net cash in China at closing.
Extension of Cash Runway
The increased proceeds from the FibroGen China sale are expected to extend the company's cash runway into the second half of 2027.
Promising Clinical Developments
Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) showed a median radiographic progression-free survival of 8.7 months, with an overall response rate of 20%.
Regulatory Milestones Achieved
FDA cleared the IND for FG-3180, a companion PET imaging agent, marking an important achievement for FibroGen.
Cost Reductions
Total operating costs and expenses for the first quarter of 2025 were $17.7 million, a decrease of 76% year-over-year.
FGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $0.30 | $0.30 | 0.00% |
Mar 17, 2025 | $0.44 | $0.35 | -20.45% |
Nov 12, 2024 | $0.39 | $0.33 | -15.38% |
Aug 06, 2024 | $0.44 | $0.46 | +4.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does FibroGen (FGEN) report earnings?
FibroGen (FGEN) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is FibroGen (FGEN) earnings time?
FibroGen (FGEN) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FGEN EPS forecast?
FGEN EPS forecast for the fiscal quarter 2025 (Q2) is -0.09.